Q1 Earnings Forecast for RNAZ Issued By HC Wainwright

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for TransCode Therapeutics in a research note issued on Wednesday, December 18th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($1.48) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q2 2025 earnings at ($1.64) EPS, Q3 2025 earnings at ($1.02) EPS and Q4 2025 earnings at ($0.78) EPS.

TransCode Therapeutics Price Performance

RNAZ opened at $3.85 on Friday. TransCode Therapeutics has a 12-month low of $3.21 and a 12-month high of $264.00. The business’s fifty day simple moving average is $395.55 and its 200-day simple moving average is $565.72.

Institutional Trading of TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management grew its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.